Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study

Psychopharmacology

Volumn 152, Issue 2, 2000, Pages 174-180

  Silvestri, S ^a   Seeman, M V ^a   Negrete, J C ^a   Houle, S ^a   Shammi, C M ^a   Remington, G J ^a   Kapur, S ^a   Zipursky, R B ^a   Wilson, A A ^a   Christensen, B K ^a   Seeman, P ^a  

^a NONE   (United States)

Author keywords

Atypical antipsychotics; D2 receptor binding; Dopamine D2 receptor upregulation; Dopaminergic hypersensitivity; PET; Tardive dyskinesia; Typical antipsychotics

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RACLOPRIDE; RISPERIDONE;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERACTIVITY; LONG TERM CARE; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SCHIZOPHRENIA; TARDIVE DYSKINESIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; DYSKINESIA; MIDDLE AGED; UPREGULATION;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED; UP-REGULATION;

EID: 0033626576     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000532     Document Type: Article

References (49)

1. Significance of dose and plasma level in the pharmacological treatment of psychosis
2. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels
3. 2 receptor density and personal detachment in healthy subjects
4. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain Science
5. In vivo assay for neuroleptic receptor binding in the striatum: Positron tomography in humans
6. The effect of antimuscarinic agents on haloperidol-induced behavioral supersensitivity
7. Concurrent treatment with benztropine and haloperidol attenuates behavioral supersensitivity but not DA receptor proliferation
8. Incidence correlates of tardive dyskinesia in first episode of schizophrenia
9. A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases
10. Striatal dopamine receptors become supersensitive while rats are given trifluperazine for 6 months
11. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects
12. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia
13. 2-dopamine receptor characteristics in neuroleptic-naive patients with schizophrenia
14. Dopamine receptors and personality traits
15. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors
16. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications
17. 2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography
18. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
19. 11C]raclopride binding using a bolus plus infusion protocol
20. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens
21. 2-dopamine receptors induced by haloperidol in rat striatum
22. Effects of smoking on haloperidol and reduced haloperidol plasma Concentrations and haloperidol clearance
23. A prospective study of tardive dyskinesia development: Preliminary results
24. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia
25. 3H-spiroperidol binding sites in rats
26. 3H-apomorphine in schizophrenic brains
27. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose
28. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol
29. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study
30. Brain neurotransmitter receptors after long-term haloperidol: Dopamine, acetylcholine, serotonin, -noradrenergic and naloxone receptors
31. Dosing the antipsychotic medication olanzapine
32. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group
33. 123I-IBZM single photon emission computerised tomography study
34. 2 dopamine receptor density
35. The effect of neuroleptic administration on cerebral dopamine receptor function
36. Assessment of striatal extracellular dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia
37. 2 receptor agonists and antagonists
38. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes
39. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases
40. Human brain dopamine receptors in children and aging adults
41. A rating scale for extrapyramidal side effects
42. Extrapyramidal symptoms in patients treated with risperidone
43. 2 occupancy in schizophrenic patients
44. Further evidence of a dose-response threshold for haloperidol in psychosis
45. Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines
46. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
47. Spontaneous orofacial dyskinesia and dopamine function in rats after 6 months of neuroleptic treatment
48. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia
49. Tardive dyskinesia in elderly psychiatric patients: A 5-year study